Royal Bank of Canada’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-6,669
| Closed | -$28K | – | 8019 |
|
|
2023
Q1 | $28K | Sell |
6,669
-10,016
| -60% | -$52K | ﹤0.01% | 5905 |
|
|
2022
Q4 | $101K | Buy |
16,685
+12,471
| +296% | +$68.1K | ﹤0.01% | 5445 |
|
|
2022
Q3 | $24K | Buy |
4,214
+3,648
| +645% | +$22.7K | ﹤0.01% | 6078 |
|
|
2022
Q2 | $3K | Buy |
566
+523
| +1,216% | +$2.68K | ﹤0.01% | 6904 |
|
|
2022
Q1 | $0 | Hold |
43
| – | – | ﹤0.01% | 8336 |
|
|
2021
Q4 | $0 | Sell |
43
-3
| -7% | -$7 | ﹤0.01% | 8324 |
|
|
2021
Q3 | $0 | Buy |
46
+3
| +7% | +$8 | ﹤0.01% | 8204 |
|
|
2021
Q2 | $0 | Hold |
43
| – | – | ﹤0.01% | 8016 |
|
|
2021
Q1 | $0 | Sell |
43
-182
| -81% | -$594 | ﹤0.01% | 7972 |
|
|
2020
Q4 | $1K | Buy |
225
+7
| +3% | +$23 | ﹤0.01% | 7029 |
|
|
2020
Q3 | $0 | Buy |
218
+175
| +407% | +$223 | ﹤0.01% | 7278 |
|
|
2020
Q2 | $0 | Hold |
43
| – | – | ﹤0.01% | 7198 |
|
|
2020
Q1 | $0 | Hold |
43
| – | – | ﹤0.01% | 7350 |
|
|
2019
Q4 | $0 | Hold |
43
| – | – | ﹤0.01% | 7413 |
|
|
2019
Q3 | $0 | Buy |
+43
| New | +$33 | ﹤0.01% | 7486 |
|
|
2018
Q4 | – | Sell |
-1,024
| Closed | -$2K | – | 7556 |
|
|
2018
Q3 | $2K | Buy |
1,024
+921
| +894% | +$2.28K | ﹤0.01% | 6566 |
|
|
2018
Q2 | $1K | Buy |
+103
| New | +$451 | ﹤0.01% | 6456 |
|
|
2018
Q1 | – | Sell |
-40
| Closed | – | – | 7255 |
|
|
2017
Q4 | $0 | Buy |
40
+22
| +122% | +$64 | ﹤0.01% | 7360 |
|
|
2017
Q3 | $0 | Buy |
+18
| New | +$60 | ﹤0.01% | 7351 |
|
|
2017
Q2 | – | Sell |
-9
| Closed | – | – | 7114 |
|
|
2017
Q1 | $0 | Buy |
+9
| New | +$42 | ﹤0.01% | 7072 |
|
|
2016
Q3 | – | Sell |
-57
| Closed | – | – | 6849 |
|
|
2016
Q2 | $0 | Buy |
+57
| New | +$262 | ﹤0.01% | 6820 |
|
|
2016
Q1 | – | Sell |
-16
| Closed | – | – | 7076 |
|
|
2015
Q4 | $0 | Sell |
16
-728
| -98% | -$9.72K | ﹤0.01% | 7227 |
|
|
2015
Q3 | $11K | Sell |
744
-174
| -19% | -$3.01K | ﹤0.01% | 5867 |
|
|
2015
Q2 | $18K | Buy |
918
+911
| +13,014% | +$17.6K | ﹤0.01% | 5772 |
|
|
2015
Q1 | $0 | Hold |
7
| – | – | ﹤0.01% | 6764 |
|
|
2014
Q4 | $0 | Buy |
7
+4
| +133% | +$92 | ﹤0.01% | 6605 |
|
|
2014
Q3 | $0 | Buy |
+3
| New | +$78 | ﹤0.01% | 6406 |
|
|
2014
Q1 | – | Sell |
-100
| Closed | -$3.42K | – | 6467 |
|
|
2013
Q4 | $2K | Buy |
100
+40
| +67% | +$728 | ﹤0.01% | 5798 |
|
|
2013
Q3 | $1K | Buy |
+60
| New | +$695 | ﹤0.01% | 6040 |
|
Other funds holding CTIC
Royal Bank of Canada's CTIC Position: Q2 2023 in Review
Royal Bank of Canada sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 6,669 shares — an estimated $28K sold.
Royal Bank of Canada first reported a position in CTIC in Q3 2013 and held it in 29 quarters. The position peaked at $101K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Royal Bank of Canada reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Royal Bank of Canada sold 6,669 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $28K.
- Royal Bank of Canada first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 29 quarters.
- Royal Bank of Canada's CTI BioPharma Corp. (DE) Common Stock position peaked at $101K in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.